Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety DisordersBusiness Wire • 02/09/22
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022Business Wire • 01/27/22
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and WesanaBenzinga • 01/11/22
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the BrainBusiness Wire • 01/11/22
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect ConferenceBusiness Wire • 12/21/21
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety DisordersBusiness Wire • 12/15/21
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use DisorderBusiness Wire • 12/08/21
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021Business Wire • 12/01/21
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related DistressBusiness Wire • 11/30/21
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021Business Wire • 11/29/21
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's UnderservedBenzinga • 11/23/21
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved CommunitiesBusiness Wire • 11/23/21
Cybin, Inc. (CYBN) CEO Doug Drysdale on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/16/21
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business HighlightsBusiness Wire • 11/15/21
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex BelserBenzinga • 11/14/21
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021Business Wire • 11/09/21
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat DepressionBenzinga • 11/09/21